Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives
Eyenovia (NASDAQ: EYEN) has engaged Chardan as financial advisor to evaluate strategic alternatives, including potential business combinations, company sale, reverse merger, or asset sale. The company is simultaneously focusing on developing its Gen-2 user-filled Optejet® device by Q3 2025 while implementing cost reduction measures of over 60%.
The company is exploring two paths for the Optejet device: a consumer 'user-filled' product through a device regulatory pathway without clinical trials, potentially available by end of year, and a proprietary drug-device combination. Eyenovia has not set a timeline for concluding the strategic review and has made no specific decisions regarding alternatives.
Eyenovia (NASDAQ: EYEN) ha incaricato Chardan come consulente finanziario per valutare alternative strategiche, comprese potenziali combinazioni aziendali, vendita della società, fusione inversa o vendita di attivi. L'azienda si sta contemporaneamente concentrando sullo sviluppo del suo dispositivo Optejet® di seconda generazione, che prevede di completare entro il terzo trimestre del 2025, mentre implementa misure di riduzione dei costi superiori al 60%.
L'azienda sta esplorando due vie per il dispositivo Optejet: un prodotto 'riempito dall'utente' attraverso un percorso normativo per dispositivi senza prove cliniche, potenzialmente disponibile entro la fine dell'anno, e una combinazione proprietaria di farmaco e dispositivo. Eyenovia non ha stabilito un termine per concludere la revisione strategica e non ha preso decisioni specifiche riguardo le alternative.
Eyenovia (NASDAQ: EYEN) ha contratado a Chardan como asesor financiero para evaluar alternativas estratégicas, incluidas posibles combinaciones empresariales, venta de la empresa, fusión inversa o venta de activos. La empresa se está enfocando simultáneamente en desarrollar su dispositivo Optejet® de segunda generación para el tercer trimestre de 2025, mientras implementa medidas de reducción de costos superiores al 60%.
La empresa está explorando dos rutas para el dispositivo Optejet: un producto 'rellenado por el usuario' a través de un camino regulatorio de dispositivos sin ensayos clínicos, disponible potencialmente a finales de año, y una combinación de fármaco y dispositivo propietario. Eyenovia no ha establecido un cronograma para concluir la revisión estratégica y no ha tomado decisiones específicas sobre alternativas.
Eyenovia (NASDAQ: EYEN)는 Chardan을 재정 고문으로 고용하여 전략적 대안을 평가하고 있으며, 여기에는 잠재적인 사업 결합, 회사 판매, 역합병 또는 자산 매각이 포함됩니다. 회사는 2025년 3분기까지 2세대 사용자 충전형 Optejet® 장치 개발에 집중하는 동시에 60% 이상의 비용 절감 조치를 시행하고 있습니다.
회사는 Optejet 장치에 대해 두 가지 경로를 탐색하고 있습니다: 임상 시험 없이 장치 규제 경로를 통한 소비자 '사용자 충전형' 제품으로, 연말까지 잠재적으로 이용 가능하며, 약물-장치 조합. Eyenovia는 전략 검토를 마무리할 일정은 설정하지 않았으며, 대안에 대한 구체적인 결정도 내리지 않았습니다.
Eyenovia (NASDAQ: EYEN) a engagé Chardan en tant que conseiller financier pour évaluer des alternatives stratégiques, y compris d'éventuelles combinaisons d'entreprises, la vente de la société, une fusion inversée ou la vente d'actifs. L'entreprise se concentre simultanément sur le développement de son dispositif Optejet® de deuxième génération rempli par l'utilisateur pour le troisième trimestre 2025, tout en mettant en œuvre des mesures de réduction des coûts de plus de 60%.
L'entreprise explore deux voies pour le dispositif Optejet : un produit 'rempli par l'utilisateur' par le biais d'un chemin réglementaire sans essais cliniques, potentiellement disponible d'ici la fin de l'année, et une combinaison médicament-dispositif propriétaire. Eyenovia n'a pas fixé de calendrier pour conclure l'examen stratégique et n'a pris aucune décision spécifique concernant les alternatives.
Eyenovia (NASDAQ: EYEN) hat Chardan als Finanzberater beauftragt, um strategische Alternativen zu bewerten, zu denen potenzielle Unternehmenszusammenschlüsse, der Verkauf des Unternehmens, Reverse Merger oder der Verkauf von Vermögenswerten gehören. Das Unternehmen konzentriert sich gleichzeitig darauf, sein Gen-2 benutzergefülltes Optejet®-Gerät bis zum dritten Quartal 2025 zu entwickeln, während es Kostenreduktionsmaßnahmen von über 60% umsetzt.
Das Unternehmen untersucht zwei Wege für das Optejet-Gerät: ein Verbraucher-„benutzergefülltes“ Produkt über einen regulatorischen Weg für Geräte ohne klinische Studien, das potenziell bis zum Jahresende verfügbar sein könnte, und eine proprietäre Arzneimittel-Geräte-Kombination. Eyenovia hat keinen Zeitrahmen für den Abschluss der strategischen Überprüfung festgelegt und keine spezifischen Entscheidungen zu Alternativen getroffen.
- Cost reduction measures of over 60% being implemented
- Potential commercialization of user-filled Optejet device by end of 2025 without clinical trials
- Dual development strategy for Optejet: consumer product and drug-device combination
- Strategic alternatives review suggests possible financial or operational challenges
- Uncertainty regarding company's future direction and potential transactions
- Extended timeline for Gen-2 Optejet development (Q3 2025)
Insights
The user-filled product strategy through a device-only regulatory pathway could significantly accelerate time-to-market compared to drug-device combinations requiring clinical trials. This dual-track approach - pursuing both strategic alternatives and operational milestones - helps preserve negotiating leverage with potential partners or acquirers.
The device's potential dual positioning - both as a consumer product and for pharmaceutical applications - expands its market opportunity. However, the substantial cost reduction may impact development timelines and capabilities. The Q3 2025 target for completing device development appears ambitious given resource constraints, though the simplified regulatory path could help offset this challenge.
The deliberate mention of multiple strategic options (sale, merger, asset sale) indicates openness to various scenarios, but also reveals potential urgency. The lack of committed timeline and standard "no assurance" language suggests early stages of the process. For potential investors, this creates a binary outcome scenario - either a value-creating transaction materializes, or the company faces continued challenges with depleted resources.
Company concurrently focused on completing development of the Gen-2 user-filled Optejet® device by 3Q 2025 while reducing spend by over
NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has engaged Chardan as its financial advisor in connection with its evaluation of strategic alternatives. With assistance from Chardan, the Company will continue to assess a full range of strategic alternatives, including but not limited to, a business combination, sale of the Company, reverse merger, asset sale, or a combination of alternatives, while also carefully managing its expenses.
Along with the evaluation of strategic alternatives, Eyenovia continues to progress development of its advanced Optejet device and is exploring options for use as both a consumer “user-filled” product and a proprietary drug-device combination. The user-filled product would advance through a device regulatory pathway without the need for clinical trials and could be commercially available by the end of this year.
The Company has not set a timetable for the conclusion of its review and has not made any decisions related to specific strategic alternatives at this time. The Company does not intend to comment further unless or until its Board of Directors has approved a definitive course of action, the review process has concluded, or it is determined that other disclosure is appropriate.
There can be no assurance that this evaluation will result in any definitive documentation to consummate one or more transactions, or other strategic changes or outcomes, or that the terms of any such transactions, changes, or outcomes will be favorable. Even if the Company enters into a definitive agreement, the Company may not be successful in completing a transaction, strategic change or outcome, or, if it completes such a transaction, strategic change or outcome, it may not ultimately enhance value or deliver expected benefits.
About Eyenovia, Inc.
Eyenovia, Inc. is an ophthalmic technology company developing its proprietary Optejet topical ophthalmic medication dispensing platform. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may combine to produce better treatment options and outcomes for patients and providers. For more information, please visit Eyenovia.com.
Forward Looking Statements
Except for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including those relating to the estimated market opportunities for our platform technology, the regulatory pathway and timing for availability of our products, and the outcome of the process to explore strategic alternatives to maximize shareholder value. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission.
In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the potential advantages of our products, and platform technology; the regulatory pathway that would apply to our products; our estimates regarding the potential market opportunity for our products; reliance on third parties to develop and commercialize our products; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our products; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products and product candidates; our competitive position; and our ability to raise additional funds and to make payments on our debt obligations as and when necessary.
Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.
Eyenovia Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com
Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363
FAQ
What strategic alternatives is Eyenovia (EYEN) considering in 2025?
When will Eyenovia's Gen-2 user-filled Optejet device be available?
How much is Eyenovia reducing its spending in 2025?
What are the two development paths for Eyenovia's Optejet device?
